FDA Requires Additional Information on DORIBAX for Treatment of Hospital-Acquired Pneumonia
... of NP, including VAP. The committee did not agree that the non-inferiority margin for the DORIBAX NP trials was appropriately justified, nor did it agree on the appropriate margin for NP trials in general. J&JPRD is confident in the NP data submitted and ...DATATRAK International Reports First Quarter Results for 2008
... a basic and diluted basis in the first quarter of 2007. The gross profit margin for the first quarter was 55% compared to 62% for the same period a year ago. The decline in gross profit margin was a result of the 41% decrease in revenue partially offset by a 30% ...Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
... of products sold 11,680 14,366 26,487 28,882 Gross margin 9,193 6,008 18,134 11,009 Selling, ... $ 20,873 $ 20,374 $ 44,621 $ 39,891 Gross margin (loss): Nabi Biologics $ 9,192 $ 5,649 $ 18,245 $ ...Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
... impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange ...New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform
... by Greenberg Quinlan Rosner Research and Public Opinion Strategies from May 7 to 12, 2009, and is available at www.healthyamericans.org . The margin of error was +/- 3.1 percent. Trust for America's Health is a non-profit, non-partisan organization dedicated to saving lives by protecting the ...AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
... along with nondiabetic subjects (n=145). The main study end-point was change from baseline in pre-bronchodilator FEV(1) at 2 years (non inferiority margin of 50 ml/year). Secondary endpoints included change from baseline in other PFT parameters (forced vital capacity, total lung capacity, and carbon ...Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors
... tumor. The tumor is then thawed by replacing the argon with helium. The procedure consists of two freezing and one thawing cycle, seeking a frozen margin beyond the tumor edge to ensure death of the entire tumor. After the cryoprobe is removed, a small bandage is placed over the skin puncture site. ...Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix
... impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange ...Velos Set to Clear 50 Percent Market Penetration of Large U.S. Clinical Research Sites by Year End
... the past few years and now includes 21 Top 25* U.S. centers. Clinical and Translational Science Award (CTSA) winners have chosen Velos by a wide margin versus all other vendors combined. Velos eResearch customers receive 47 percent of extramural clinical research funding from the National Institutes ...Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
... clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "TR-701's potential for once-daily ...Genta Incorporated Announces Third Quarter 2007 Financial Results
... - net $115 $145 $314 $591 Cost of goods sold 20 41 68 79 Gross margin 95 104 246 512 Operating expenses: Research and development 4,763 8,514 12,244 ...NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
... an increasing burden on medical services. Furthermore, the clinical data on NCX 1022 suggest that nitric oxide donation may also improve the safety margin over current treatments. We will continue to work closely with Ferrer to bring our promising drug candidate into clinical trials." NicOx and Ferrer ...Aspirin Named 8th World Wonder by Majority of Americans
... Corporation conducted a survey on current wonders from March 30, 2007 through April 2, 2007 among 1,038 American consumers via telephone. The margin of error is +/- 3%. About Bayer Consumer Care The Consumer Care Division of Bayer HealthCare LLC, is headquartered in Morristown, N.J. Bayer's ...Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
... - net $105 $379 $199 $446 Cost of goods sold 26 22 48 38 Gross margin 79 357 151 408 Operating expenses: Research and development 4,099 8,637 7,481 ...Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
... of mortality at 30 days after injury. The margin to assess noninferiority, using the upper ... endpoint requires the establishment of a relative margin around the control outcome. The margin to assess noninferiority in this study, using the ...Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
... certified gastroenterologists in the U.S. Assuming no sample bias, the margin of error for the sample of 451 UC patients is +/- 5 percent; assuming no sample bias, the margin of error for a sample of 300 (the other surveys) is +/- 6 percent. For ...CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
... higher than those that have provided maximum therapeutic benefit in animals. Second, using less than the highest possible dose potentially provides a margin of safety for ALS patients. Finally, larger doses may not be practical in this population as the capsules could be too large for ALS patients who ...Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
... over long-term use is common. The Directors believe that today’s result is highly important because it shows that HMPL-004 has a similar margin of effect yet offers a different mechanism of action and therefore provides a direct alternative to the current best standard of care. If ultimately ...